• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食管胃交界腺癌的临床病理特征及生存预测:一项基于监测、流行病学和最终结果(SEER)数据库的回顾性研究

Clinicopathological Characteristics and Survival Predictions for Adenocarcinoma of the Esophagogastric Junction: A SEER Population-Based Retrospective Study.

作者信息

Liu Xin, Jiang Qingtao, Yue Chao, Wang Qin

机构信息

Department of Prevention and Control for Occupational Disease, Jiangsu Provincial Center for Disease Control and Prevention & Jiangsu Preventive Medicine Association, Nanjing, People's Republic of China.

Department of Clinical Medicine, Jiangsu Health Vocational College, Nanjing, People's Republic of China.

出版信息

Int J Gen Med. 2021 Dec 24;14:10303-10314. doi: 10.2147/IJGM.S341405. eCollection 2021.

DOI:10.2147/IJGM.S341405
PMID:34992445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8714080/
Abstract

OBJECTIVE

Adenocarcinoma of the esophagogastric junction (AEJ) is a relatively rare malignancy in Western countries whose specific clinicopathological characteristics and associated prognosis have not been comprehensively described.

METHODS

Data on patients with AEJ between 2005 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) database were extracted, evaluated, and compared with patients with gastric cancer (GC) in general. Overall survival (OS) was evaluated using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model to identify risk factors predictive for OS, and the results were used to construct a nomogram to predict 1-, 3-, and 5-year OS among patients with AEJ.

RESULTS

A total of 8013 patients diagnosed with AEJ were identified from the records of 30,179 patients with GC. The mean age was 65.4 (SD = 12.0) years, 79.5% were men, 87.2% were Caucasian, 91.5% were moderately-to-poorly differentiated, 34.4% had AJCC stage I AEJ, and 28.8% had stage IV. The median OS was 18 months, and the 5-year OS was 25.8% (95% CI: 24.8-26.8%). Fewer patients with AEJ had undergone surgical resection, fewer had T+ and N+ (N2~N3) disease ( < 0.001), and fewer had distant metastases compared to the patients with GC ( < 0.05). In the univariate and multivariate analyses, age, race, summary stage, N stage, M stage, and surgery were identified as independent risk factors. The nomogram had a calibration index of 0.726.

CONCLUSION

AEJ was found to have distinct clinicopathological characteristics. Age, race, summary stage, N stage, M stage, and surgery were independently associated with OS. The nomogram accurately predicted 1-, 3-, and 5-year OS rates.

摘要

目的

食管胃交界腺癌(AEJ)在西方国家是一种相对罕见的恶性肿瘤,其具体的临床病理特征及相关预后尚未得到全面描述。

方法

提取、评估监测、流行病学和最终结果(SEER)数据库中2005年至2015年AEJ患者的数据,并与一般胃癌(GC)患者的数据进行比较。采用Kaplan-Meier法评估总生存期(OS)。使用Cox比例风险回归模型进行单因素和多因素分析,以确定预测OS的危险因素,并将结果用于构建列线图,以预测AEJ患者1年、3年和5年的OS。

结果

从30179例GC患者记录中确定了8013例诊断为AEJ的患者。平均年龄为65.4(标准差=12.0)岁,79.5%为男性,87.2%为白种人,91.5%为中低分化,34.4%为AJCC I期AEJ,28.8%为IV期。中位OS为18个月,5年OS为25.8%(95%CI:24.8-26.8%)。与GC患者相比,接受手术切除的AEJ患者更少,T+和N+(N2~N3)疾病患者更少(<0.001),远处转移患者更少(<0.05)。在单因素和多因素分析中,年龄、种族、总分期、N分期、M分期和手术被确定为独立危险因素。列线图的校准指数为0.726。

结论

发现AEJ具有独特的临床病理特征。年龄、种族、总分期、N分期、M分期和手术与OS独立相关。列线图准确预测了1年、3年和5年的OS率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/b967319b9e78/IJGM-14-10303-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/f79766d3b6c6/IJGM-14-10303-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/cef5da3a7c2b/IJGM-14-10303-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/0fe6d33d35c4/IJGM-14-10303-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/c6f2394a7ae0/IJGM-14-10303-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/a70941f9f1c2/IJGM-14-10303-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/b967319b9e78/IJGM-14-10303-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/f79766d3b6c6/IJGM-14-10303-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/cef5da3a7c2b/IJGM-14-10303-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/0fe6d33d35c4/IJGM-14-10303-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/c6f2394a7ae0/IJGM-14-10303-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/a70941f9f1c2/IJGM-14-10303-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5af/8714080/b967319b9e78/IJGM-14-10303-g0006.jpg

相似文献

1
Clinicopathological Characteristics and Survival Predictions for Adenocarcinoma of the Esophagogastric Junction: A SEER Population-Based Retrospective Study.食管胃交界腺癌的临床病理特征及生存预测:一项基于监测、流行病学和最终结果(SEER)数据库的回顾性研究
Int J Gen Med. 2021 Dec 24;14:10303-10314. doi: 10.2147/IJGM.S341405. eCollection 2021.
2
Clinicopathological characteristics and prognosis of pulmonary pleomorphic carcinoma: a population-based retrospective study using SEER data.肺多形性癌的临床病理特征及预后:一项基于监测、流行病学和最终结果(SEER)数据的人群回顾性研究
J Thorac Dis. 2018 Jul;10(7):4262-4273. doi: 10.21037/jtd.2018.06.71.
3
[Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].食管胃交界腺癌与胃窦腺癌临床病理特征及预后的比较
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Feb 25;22(2):149-155.
4
Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma.纯黏液性腺癌的临床病理特征、遗传表型及预后分析。
Cancer Med. 2020 Jan;9(2):517-529. doi: 10.1002/cam4.2726. Epub 2019 Nov 25.
5
Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification.食管胃结合部腺癌应归类为食管癌吗?根据第七版 AJCC TNM 分类的比较分析。
Ann Surg. 2012 May;255(5):908-15. doi: 10.1097/SLA.0b013e31824beb95.
6
[Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].[UICC-AJCC第7版食管癌和胃癌TNM分期系统对食管胃交界腺癌(SiewertⅡ型)预后预测价值的评估]
Zhonghua Zhong Liu Za Zhi. 2014 Dec 23;36(12):916-21. doi: 10.3760/cma.j.issn.0253-3766.2014.12.008.
7
Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma.预测肾集合管细胞癌患者总生存和癌症特异性生存的预后因素和列线图。
Biomed Res Int. 2021 Nov 11;2021:6736008. doi: 10.1155/2021/6736008. eCollection 2021.
8
Clinicopathological features and prognosis of patients with esophageal cancer as the second primary cancer: a large population-based analysis using the SEER program [2000-2015].作为第二原发性癌症的食管癌患者的临床病理特征及预后:基于监测、流行病学与最终结果(SEER)计划[2000 - 2015年]的大型人群分析
Transl Cancer Res. 2020 Feb;9(2):1113-1124. doi: 10.21037/tcr.2019.12.64.
9
A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.卵巢黏液性囊腺癌患者的预后模型:基于人群的分析。
J Ovarian Res. 2022 Feb 16;15(1):26. doi: 10.1186/s13048-022-00958-6.
10
A novel nomogram for predicting survival of patients with poorly differentiated gastric adenocarcinoma.一种用于预测低分化胃腺癌患者生存情况的新型列线图。
Transl Cancer Res. 2021 Feb;10(2):886-898. doi: 10.21037/tcr-20-2794.

引用本文的文献

1
Association Between CDK4/CDK6 Expression and Prognosis in Patients with Adenocarcinoma of Gastroesophageal Junction.CDK4/CDK6表达与食管胃交界腺癌患者预后的关系
Dig Dis Sci. 2025 Jun 17. doi: 10.1007/s10620-025-09136-2.
2
Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development.鉴定CD66c作为胃食管交界癌中抗体药物偶联物开发的潜在靶点。
Gastric Cancer. 2025 May;28(3):422-441. doi: 10.1007/s10120-025-01584-z. Epub 2025 Feb 7.
3
Neural network-based prognostic predictive tool for gastric cardiac cancer: the worldwide retrospective study.

本文引用的文献

1
A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.胃癌术前预测淋巴结转移的基因组-临床病理列线图
BMC Cancer. 2021 Apr 23;21(1):455. doi: 10.1186/s12885-021-08203-x.
2
Validation of Tools for Predicting Incident Adenocarcinoma of the Esophagus or Esophagogastric Junction.预测食管或食管胃交界腺癌发病工具的验证
Am J Gastroenterol. 2021 May 1;116(5):949-957. doi: 10.14309/ajg.0000000000001255.
3
Novel Histologic Categorization Based on Lauren Histotypes Conveys Prognostic Information for Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.
基于神经网络的贲门癌预后预测工具:全球回顾性研究
BioData Min. 2023 Jul 18;16(1):21. doi: 10.1186/s13040-023-00335-z.
4
Nomogram for predicting the likelihood of liver metastases at initial diagnosis in patients with Siewert type II gastroesophageal junction adenocarcinoma.预测 Siewert Ⅱ型胃食管结合部腺癌患者初始诊断时肝转移可能性的列线图。
Sci Rep. 2023 Jul 7;13(1):11032. doi: 10.1038/s41598-023-37318-3.
5
A novel nomogram based on clinical blood indicators for prognosis prediction in curatively resected esophagogastric junction adenocarcinoma patients.一种基于临床血液指标的新型列线图,用于预测接受根治性切除的食管胃交界腺癌患者的预后。
J Cancer. 2023 May 21;14(9):1553-1561. doi: 10.7150/jca.83588. eCollection 2023.
6
Analysis of immune status in gastric adenocarcinoma with different infiltrating patterns and origin sites.不同浸润模式和起源部位胃腺癌患者免疫状态分析。
Front Immunol. 2022 Aug 23;13:978715. doi: 10.3389/fimmu.2022.978715. eCollection 2022.
基于劳伦组织学类型的新型组织学分类为胃食管交界癌传递预后信息——来自德国一个大型单中心队列的分析
Cancers (Basel). 2021 Mar 15;13(6):1303. doi: 10.3390/cancers13061303.
4
Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study.食管胃交界腺癌与胃腺癌具有共同特征:文献综述与回顾性多中心队列研究
Ann Gastroenterol Surg. 2020 Oct 26;5(1):46-59. doi: 10.1002/ags3.12406. eCollection 2021 Jan.
5
Advances in the surgical management of gastric and gastroesophageal junction cancer.胃及胃食管交界癌手术治疗的进展
Transl Gastroenterol Hepatol. 2021 Jan 5;6:16. doi: 10.21037/tgh.2020.02.06. eCollection 2021.
6
Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction.与胃食管交界处腺癌药物脆弱性和预后相关的基因组和转录组改变。
Nat Commun. 2020 Nov 30;11(1):6091. doi: 10.1038/s41467-020-19949-6.
7
Current status of proximal gastrectomy for gastric and esophagogastric junctional cancer: A review.胃及食管胃交界部癌近端胃切除术的现状:综述
Ann Gastroenterol Surg. 2020 Jun 21;4(5):498-504. doi: 10.1002/ags3.12365. eCollection 2020 Sep.
8
Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.基于临床病理、分子、免疫和生存分析的微卫星不稳定性低食管胃结合部腺癌的免疫原性特征。
Int J Cancer. 2021 Mar 1;148(5):1260-1275. doi: 10.1002/ijc.33322. Epub 2020 Oct 10.
9
Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction.采用质子或光子放疗的新辅助放化疗治疗食管腺癌和胃食管交界腺癌后的病理完全缓解(pCR)率及预后。
J Gastrointest Oncol. 2020 Aug;11(4):663-673. doi: 10.21037/jgo-20-205.
10
Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines.美国镭协会可手术食管癌和食管胃交界腺癌合理使用标准执行摘要:系统评价与指南
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):186-200. doi: 10.1016/j.ijrobp.2020.08.050. Epub 2020 Aug 25.